Actavia Life Sciences, Inc. (RASP)

Actavia Life Sciences Income Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Mar 31, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020	Sep 30, 2019
Selling, General & Admin	0.25	0.29	0.3	0.19	0.56	0.9
Research & Development	0.09	0.09	0.08	0.06	-	0.01
Operating Expenses	0.35	4.24	0.38	0.25	0.56	0.92
Operating Income	-0.35	-4.24	-0.38	-0.25	-0.56	-0.92
Interest Expense	-0.06	-0.21	-0.94	-0.52	-0.04	-0.03
Currency Exchange Gain (Loss)	-	-	-	-0	0	-0
Other Non Operating Income (Expenses)	0	0.01	0.11	-	-	-
EBT Excluding Unusual Items	-0.41	-4.44	-1.21	-0.76	-0.6	-0.94
Impairment of Goodwill	-	-	-	-	-2.72	-
Gain (Loss) on Sale of Assets	-	-	-	-	0.12	-
Asset Writedown	-	-	-	-	-2.15	-
Other Unusual Items	-	-	0.53	-0.11	-	-
Pretax Income	-0.41	-4.44	-0.69	-0.88	-5.35	-0.94
Income Tax Expense	-	-	-	-	-0	-0.01
Net Income	-0.41	-4.44	-0.69	-0.88	-5.35	-0.94
Net Income to Common	-0.41	-4.44	-0.69	-0.88	-5.35	-0.94
Shares Outstanding (Basic)	772	578	111	69	69	69
Shares Outstanding (Diluted)	772	578	111	69	69	69
Shares Change (YoY)	186.81%	418.75%	61.70%	-	-	-
EPS (Basic)	-0.00	-0.01	-0.01	-0.01	-0.08	-0.01
EPS (Diluted)	-0.00	-0.01	-0.01	-0.01	-0.08	-0.01
Free Cash Flow	-0.07	-0.01	-0.31	-0.29	-0.25	-0.09
Free Cash Flow Per Share	-	-	-0.00	-0.00	-0.00	-0.00
EBITDA	-	-	-0.38	-0.25	-0.55	-0.91
D&A For EBITDA	-	-	0	0	0	0
EBIT	-0.35	-4.24	-0.38	-0.25	-0.56	-0.92

Updated May 20, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.